53. (New) The antibody or fragment thereof of claim 50 which is a polyclonal antibody.

- 54. (New) The antibody or fragment thereof of claim 50 which is selected from the group consisting of:
 - (a) a chimeric antibody;
 - (b) a humanized antibody;
 - (c) a single chain antibody; and
 - (d) a Fab fragment.
- 55. (New) The antibody or fragment thereof of claim 50 which is labeled.
- 56. (New) The antibody or fragment thereof of claim 55, wherein the label is selected from the group consisting of:
 - (a) an enzyme;
 - (b) a fluorescent label;
 - (c) a luminescent label; and
 - (d) a bioluminescent label.
- 57. (New) The antibody or fragment thereof of claim 50, wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.
- 58. (New) The antibody or fragment thereof of claim 50, wherein said antibody or fragment thereof specifically binds to said protein in an ELISA.

Serial No.: 09/731,816

Docket No. PF470P1

59. (New) An isolated cell that produces the antibody or fragment thereof of claim 50.

60. (New) A hybridoma that produces the antibody or fragment thereof of claim 50.

61. (New) A method of detecting IL-22 protein in a biological sample comprising:

(a) contacting the biological sample with the antibody or fragment thereof of claim 50, and

 $\sqrt{(b)}$ detecting the IL-22 protein in the biological sample.

62. (New) The method of claim 61, wherein the antibody or fragment thereof is a polyclonal antibody.

63. (New) An isolated antibody or fragment thereof obtained from an animal that has been immunized by a protein consisting of amino acid sequence 1 to 160 of SEQ ID NO:4, wherein said antibody or fragment thereof specifically binds to said amino acid sequence.

- 64. (New) The antibody or fragment thereof of claim 63 which is a monoclonal antibody.
- 65. (New) The antibody or fragment thereof of claim 63 which is selected from the group consisting of:

"Serial No.: 09/731,816 Docket No. PF470P1

(a) a chimeric antibody;

- (b) a polyclonal antibody;
- (c) a humanized antibody;
- (d) a single chain antibody; and
- (e) a Fab fragment.
- 66. (New) An isolated monoclonal antibody or fragment thereof that specifically binds to a protein consisting of amino acid residues 1 to 160 of SEQ ID NO:4.
- 67. (New) The antibody or fragment thereof of claim 66, wherein said protein bound by said antibody or fragment thereof is glycosylated.
- 68. (New) The antibody or fragment thereof of claim 66 which is a human antibody.
- 69. (New) The antibody or fragment thereof of claim 66 which is selected from the group consisting of:
 - (a) a chimeric antibody;
 - (b) a humanized antibody;
 - (c) a single chain antibody; and
 - (d) a Fab fragment.
- 70. (New) The antibody or fragment thereof of claim 66 which is labeled.
- 71. (New) The antibody or fragment thereof of claim 70, wherein the label is selected from the group consisting of:
 - (a) an enzyme;

. Serial No.: 09/731,816 Docket No. PF470P1

- (b) a fluorescent label;
- (c) a luminescent label; and
- (d) a bioluminescent label.
- 72. (New) The antibody or fragment thereof of claim 66, wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.
- 73. (New) The antibody or fragment thereof of claim 66, wherein said antibody or fragment thereof specifically binds to said protein in an ELISA.
- 74. (New) An isolated cell that produces the antibody or fragment thereof of claim 66.
- 75. (New) A hybridoma that produces the antibody or fragment thereof of claim 66.

76. (New) A method of detecting IL-22 protein in a biological sample comprising:

(a) contacting the biological sample with the antibody or fragment thereof of claim 66; and

(b) detecting the IL-22 protein in the biological sample.

Serial No.: 09/731,816 Docket No. PF470P1

77. (New) An isolated antibody or fragment thereof that specifically binds to a protein consisting of the complete polypeptide encoded by the cDNA contained in ATCC Deposit Number 209665.

- 78. (New) The antibody or fragment thereof of claim 77, wherein said protein bound by said antibody or fragment thereof is glycosylated.
- 79. (New) The antibody or fragment thereof of claim 77 which is a human antibody.
- 80. (New) The antibody or fragment thereof of claim 77 which is a polyclonal antibody.
- 81. (New) The antibody or fragment thereof of claim 77 which is selected from the group consisting of:
 - (a) a chimeric antibody;
 - (b) a humanized antibody;
 - (c) a single chain antibody; and
 - (d) a Fab fragment.
- 82. (New) The antibody or fragment thereof of claim 77 which is labeled.
- 83. (New) The antibody or fragment thereof of claim 82, wherein the label is selected from the group consisting of:
 - (a) an enzyme;

Serial No.: 09/731,816 Docket No. PF470P1

- (b) a fluorescent label;
- (c) a luminescent label; and
- (d) a bioluminescent label.
- 84. (New) The antibody or fragment thereof of claim 77, wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.
- 85. (New) The antibody or fragment thereof of claim 77, wherein said antibody or fragment thereof specifically binds to said protein in an ELISA.
- 86. (New) An isolated cell that produces the antibody or fragment thereof of claim 77.
- 87. (New) A hybridoma that produces the antibody or fragment thereof of claim 77.

88. (New) A method of detecting IL-22 protein in a biological sample comprising:

(a) contacting the biological sample with the antibody or fragment thereof of claim 77 and

- (b) detecting the IL-22 protein in the biological sample.
- 89. (New) The method of claim 88, wherein the antibody or fragment thereof is a polyclonal antibody.

Serial No.: 09/731,816 Docket No. PF470P1

or Bo

90. (New) An isolated antibody or fragment thereof obtained from an animal that has been immunized with a protein consisting of the amino acid sequence of the complete polypeptide encoded by the cDNA contained in ATCC Deposit Number 209665, wherein said antibody or fragment thereof specifically binds to said amino acid sequence.

- 91. (New) The antibody or fragment thereof of claim 90 which is a monoclonal antibody.
- 92. (New) The antibody or fragment thereof of claim 90 which is selected from the group consisting of:
 - (a) a chimeric antibody;
 - (b) a polyclonal antibody;
 - (c) a humanized antibody;
 - (d) a single chain antibody; and
 - (e) a Fab fragment.
- 93. (New) An isolated monoclonal antibody or fragment thereof that specifically binds to a protein consisting of the complete polypeptide encoded by the cDNA contained in ATCC Deposit Number 209665.
- 94. (New) The antibody or fragment thereof of claim 90, wherein said protein bound by said antibody or fragment thereof is glycosylated.
- 95. (New) The antibody or fragment thereof of claim 90 which is a human antibody.

96. (New) The antibody or fragment thereof of claim 90 which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a humanized antibody;
- (c) a single chain antibody; and
- (d) a Fab fragment.
- 97. (New) The antibody or fragment thereof of claim 90 which is labeled.
- 98. (New) The antibody or fragment thereof of claim 97, wherein the label is selected from the group consisting of:
 - (a) an enzyme;
 - (b) a fluorescent label;
 - (c) a luminescent label; and
 - (d) a bioluminescent label.
- 99. (New) The antibody or fragment thereof of claim 90, wherein said antibody or fragment thereof specifically binds to said protein in a Western blot.
- 100. (New) The antibody or fragment thereof of claim 90, wherein said antibody or fragment thereof specifically binds to said protein in an ELISA.
- 101. (New) An isolated cell that produces the antibody or fragment thereof of claim 90.

102. (New) A hybridoma that produces the antibody or fragment thereof of claim 90.

103. (New) A method of detecting IL-22 protein in a biological sample comprising:

(a) contacting the biological sample with the antibody or fragment thereof

of claim 90; and

(b) detecting the IL-22 protein in the biological sample.